We here focused on exploring the expression of AF1q in samples of patients operated on for GC as well as AF1q’s relation to tumoral CD44 expression; secondly, we aimed to elicit AF1q’s potential as a prognostic marker for GC survival. This evidence concerns the gene CD44 and gastric cancer.